Information  X 
Enter a valid email address

Kromek Group PLC (KMK)

  Print      Mail a friend

Wednesday 13 January, 2021

Kromek Group PLC

Funding to advance Bio-Threat Detection solution

RNS Number : 4715L
Kromek Group PLC
13 January 2021
 

13 January 2021

 

Kromek Group plc

("Kromek" or the "Group")

 

Kromek receives Innovate UK funding to advance Biological-Threat Detection solution

Funding received for customisation of system for automated detection of airborne SARS-CoV-2 and identification of novel and mutating viruses

 

Kromek (AIM: KMK), a worldwide supplier of detection technology focusing on the medical, security screening and nuclear markets, announces that it has commenced a £1.25m programme funded by Innovate UK to customise its biological threat-detection solution for the automated detection of all airborne viruses, including COVID-19, to support end-use cases.

 

The Group's solution is designed to be deployed in high footfall locations, such as airports, hospitals, retail outlets and entertainment venues. The base technology, which is fully developed, samples the air in-situ to detect and analyse airborne pathogens using DNA sequencing. In response to the pandemic, the initial focus is on productising the technology to develop a system that will rapidly test for the presence of SARS-CoV-2, the virus that causes COVID-19. It will run automatically and the results will not require analysis by trained individuals or specialist laboratories.

 

By detecting the virus in the air in real time, rather than solely relying on the testing of individuals or development of symptoms in individuals, the system will enable earlier identification of potential infection exposure to help reduce transmission. It will also support facilities management such as by enabling site operators to know what level of ventilation is required from the HVAC system or when decontamination is necessary.

 

In addition, the system will have the capability to test for a wide spectrum of viruses, including mutations of SARS-CoV-2. This will support the development of a bio-resilience solution against the spread of new strains of COVID-19 or other novel viruses that could result in future pandemics.

 

Kromek is engaging with potential customers for the COVID-19 detection system to develop deployment models and identify how it can best fit their needs. The Group will provide any necessary customisation of the system ahead of piloting by those user groups. The Group expects the first pilots with potential users to commence by the end of this financial year and anticipates commercial deployment in 2021/22.

 

The funding has been awarded under an 18-month programme of UK Research and Innovation ("UKRI"), which is a non-departmental public body sponsored by the UK government's Department for Business, Energy and Industrial Strategy that brings together the UK's seven research councils, Innovate UK and Research England. The programme seeks to support the development of solutions to address and mitigate the health, social, economic, cultural and environmental impacts of the COVID-19 outbreak.

 

Dr Arnab Basu, CEO of Kromek, said: "We are very pleased to have received backing from UKRI and Innovate UK to progress the deployment of our solution for the detection of airborne COVID-19. Our system can augment the government's Test and Trace system by enabling early identification of potential exposure to the virus while supporting the safe return of visitors to public spaces like mass transport, retail outlets and entertainment venues. We also believe that the continuous monitoring with our system, which can test for a wide spectrum of viruses as well as mutations of COVID-19, has significant potential for protecting against the outbreak of pandemics in the future." 

 

 

For further information, please contact:

 

Kromek Group plc

+44 (0)1740 626 060

Arnab Basu, CEO

Paul Farquhar, CFO

 

 

Cenkos Securities plc (Nominated Adviser and Broker)

+44 (0)20 7397 8900

Max Hartley (NOMAD)

Julian Morse (Sales)

 

 

Luther Pendragon (PR)

+44 (0)20 7618 9100

Harry Chathli

Claire Norbury

Alexis Gore

Joe Quinlan

 

 

 

About Kromek Group plc

 

Kromek Group plc is a technology group (global HQ in County Durham) and a leading developer of high performance radiation detection products based on cadmium zinc telluride ("CZT") and other advanced technologies. Using its core technology platforms, Kromek designs, develops and produces x-ray and gamma ray imaging and radiation detection products for the medical, security screening and nuclear markets.

 

The Group's products provide high resolution information on material composition and structure and are used in multiple applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, and the analysis of radioactive materials.

 

The Group's business model provides a vertically integrated technology offering to customers, from radiation detector materials to finished products or detectors, including software, electronics and application specific integrated circuits ("ASICs").

 

The Group has operations in the UK and US (California and Pennsylvania), and is selling internationally through a combination of distributors and direct OEM sales.

 

Currently, the Group has over one hundred full-time employees across its global operations. Further information on Kromek Group is available at www.kromek.com and

https://twitter.com/kromekgroup .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFFFEVLTIFLIL

a d v e r t i s e m e n t